(Q34731136)

4 August 2017

Phase II study of elliptinium acetate salvage treatment of advanced breast cancer (English)

1 reference

4 August 2017

Rouëssé J

1

1 reference

4 August 2017

Spielmann M

2

1 reference

4 August 2017

Turpin F

3

1 reference

4 August 2017

Le Chevalier T

4

1 reference

4 August 2017

Azab M

5

1 reference

4 August 2017

Mondésir JM

6

1 reference

4 August 2017

1 January 1993

1 reference

European Journal of Cancer

4 August 2017

1 reference

4 August 2017

29A

1 reference

4 August 2017

6

1 reference

4 August 2017

856-859

1 reference

Alkaloids of Ochrosia maculata Jacq. (Ochrosia borbonica Gmel.). Isolation of the alkaloids and study of the antitumor properties of 9-methoxyellipticine

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Autoxidation of the antitumor drug 9-hydroxyellipticine and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Drug dependent red cell antibodies and intravascular haemolysis occurring in patients treated with 9 hydroxy-methyl-ellipticinium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Elliptinium: phase II study in advanced measurable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

Elliptinium acetate in metastatic breast cancer--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980424-1

7 January 2021

10.1016/S0959-8049(05)80424-1

Identifiers

DOI

1 reference

4 August 2017

1 reference